Scientific Letters
Vol. 13 No. 1 (2021): Mediterranean Journal of Hematology and Infectious Diseases, Volume 13, 2021
https://doi.org/10.4084/MJHID.2021.042

Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: March 24, 2021
Accepted: May 12, 2021
Published: June 28, 2021
1204
Views
384
Downloads
156
HTML
CLL, symptomatic COVID19 , Venetoclax-rituximab, time-limited therapy

Authors

Stefano Molica
smolica@libero.it
smolica@libero.it, .
Paolo Sportoletti
2) Centro di Ricerca Emato-Oncologica (CREO), University of Perugia, Perugia, Italy, Italy.
Nicola Di Renzo
3) U.O.C. Ematologia, Presidio Ospedaliero Vito Fazi, Lecce, Italy, Italy.
Pellegrino Musto
4) Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Aldo Moro" University School of Medicine, 70124 Bari, Italy, Italy.
Fabrizio Pane
5) Department of Clinical Medicine and Surgery, Hematology Unit, Federico II University Medical School, Naples, Italy, Italy.
Francesco Di Raimondo
6) Division of Hematology, Department of Surgery and Medical Specialties, University of Catania, Policlinico, Italy, Italy.

With more than 3 million proven infections and 100.000 associated deaths in Italy, the COVID-19 pandemic poses extraordinary challenges to health-care professionals and especially to those caring for patients with haematologic malignancies  (1-2). Given the multiple   immune  defects characterizing chronic lymphocytic leukaemia (CLL), it is considered that patients with this form of leukemia have a high-risk of suffering severe forms of COVID-19 (3-4).

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
https://coronavirus.jhu.edu/map.html
Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020 Oct;7(10):e737-e745.
Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015 Jul 30;126(5):573-581.
Langerbeins P, Eichhorst B. Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic. Acta Haematol . 2021 Feb 25;1-11. doi: 10.1159/000514071. Online ahead of print.
Koffman B, Mato A, Byrd JC, Danilov A, Hedrick B, Ujjani C,et al Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol. 2020 Aug;95(8):E199-E203.
Baumann T, Delgado J, Montserrat E. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report. Leukemia. 2020 Jul;34(7):1954-1956.
Thibaud S, Tremblay D, Bhalla S, Zimmerman B, Sigel K, Gabrilove J. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19. Br J Haematol 2020 Jul;190(2):e73-e76.
Cuneo A, Scarfò L, Reda G, Varettoni M, Quaglia FM, Marchetti M, et al Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. Blood. 2020 Aug 6;136(6):763-766.
Sehn LH, Kuruvilla P, Christofides A, Stakiw J. Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic. Curr Oncol. 2020 Jun;27(3):e332-e335.
Reda G, Noto A, Cassin R, Zamprogna G, Borella C, Scarfò L, et al. Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL). Leukemia. 2020 Sep;34(9):2531-2532.
Rossi D, Shadman M, Condoluci A, Brown JR, Byrd JC, Gaidano G,et al How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. Hemasphere. 2020 Jul 30;4(4):e432.
Montserrat E. When CLL meets COVID-19. Blood. 2020 Sep 3;136(10):1115-1116.
Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020 Sep;34(9):2354-2363.
Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020 Sep 3;136(10):1134-1143.
https://www.hematology.org/covid-19/covid-19-and-cll. COVID-19 and CLL: Frequently Asked Questions (Version 4.1; last updated February 2, 2021).
https://ehaweb.org/covid-19/covid-19-recommendations/recommendations-for-specific-hematologic-malignancies. COVID-19 and CLL: Frequently Asked Questions (Produced by the EHA SWG on CLL (ERIC) and endorsed by EHA).
Shadman M, Ujjani C. Vaccinations in CLL: implications for COVID-19. Blood
14;137(2):144-146.
Roeker LE, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA, et al.
Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia 2020 Nov;34(11):3047-3049.
Stefano Molica, smolica@libero.it

How to Cite



“Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy”. (2021) Mediterranean Journal of Hematology and Infectious Diseases, 13(1), p. e2021042. doi:10.4084/MJHID.2021.042.
Copyright (c) 2021 Stefano Molica, Paolo Sportoletti, Nicola Di Renzo, Pellegrino Musto, Fabrizio Pane, Francesco Di Raimondo Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.